A doxorubicin-CNGRC-peptide conjugate with prodrug properties

被引:72
作者
van Hensbergen, Y [1 ]
Broxterman, HJ [1 ]
Elderkamp, YW [1 ]
Lankelma, J [1 ]
Beers, JCC [1 ]
Heijn, M [1 ]
Boven, E [1 ]
Hoekman, K [1 ]
Pinedo, HM [1 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands
关键词
aminopeptidase N; CD13; doxorubicin; doxorubicin-peptide conjugate; prodrug; tumor vasculature;
D O I
10.1016/S0006-2952(01)00928-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is increasing interest in the exploitation of molecular addresses for the targeting of tumor imaging or therapeutic agents. A recent study demonstrated anticancer activity in human xenografts of doxorubicin (DOX)-peptide conjugates targeted to the tumor vascular endothelium, among them DOX coupled to the cyclic pentapeptide CNGRC [Science 279 (1998) 377]. In order to learn more about the mechanism of action of this type of DOX-peptide conjugates, we have studied the interaction of DOX-CNGRC with primary human umbilical cord vein endothelial cells (HUVEC) and tumor cells under defined in vitro conditions. We used a DOX conjugate, in which the cyclic CNGRC peptide, for which an in vivo endothelial address has recently been identified as aminopeptidase N (APN)/CD13, has been coupled via a hydrolysable spacer to the C-14 anthracycline-side chain. First we determined that the t(1/2) of DOX-CNGRC conjugate in human blood was 442 min (at 37degrees) allowing sufficient time for endothelial targeting when administered i.v. When cultured cells were exposed for 30 min to DOX-CNGRC a more cytoplasmic localization of fluorescent drug was seen when compared to DOX exposure and intracellular DOX-CNGRC was identified after extraction from the cells. This revealed differences in the cellular uptake process of the conjugate compared to DOX. The antiproliferative effect of DOX-CNGRC was determined by 30 min exposure in medium with a high protein content in order to mimick the in vivo targeting situation. In this medium, the IC50 was 1.1 muM for highly CD13 expressing HT-1080, 1.45 muM for CD 13 negative SK-UT-1 sarcoma cells and 6.5 muM for CD13 positive HUVEC. The IC50 of DOX for these cells were 1.0, 2.0 and 7.3 muM, respectively. Although DOX-CNGRC inhibited the peptidase activity of CD 13 up to 5017(, our data do not favor an important role for the enzyme inhibition in the cytotoxic effect of the conjugate. The antitumor activity was tested in nude mice bearing human ovarian cancer xenografts (OVCAR-3). A weekly i.v. administration (3 mg/kg DOX-equivalent. 3x) showed a minor (40 7() growth delay, which does not indicate efficacy better than that expected for free DOX. In conclusion, this study indicates that the antiproliferative and anti-angiogenic effects of DOX-CNGRC as reported before, are likely caused by the cytostatic effects of intracellularly released parent drug DOX, independent of CD13 expression/activity. More research is needed to identify the optimal specific chemical configuration of DOX-peptide conjugates for in vivo targeting and receptor-mediated cellular uptake. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:897 / 908
页数:12
相关论文
共 40 条
  • [1] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [2] Cancer research - Peptide-guided cancer drugs show promise in mice
    Barinaga, M
    [J]. SCIENCE, 1998, 279 (5349) : 323 - 324
  • [3] CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
    Bhagwat, SV
    Lahdenranta, J
    Giordano, R
    Arap, W
    Pasqualini, R
    Shapiro, LH
    [J]. BLOOD, 2001, 97 (03) : 652 - 659
  • [4] DOXORUBICIN COMPARED WITH RELATED-COMPOUNDS IN A NUDE-MOUSE MODEL FOR HUMAN OVARIAN-CANCER
    BOVEN, E
    SCHLUPER, HMM
    ERKELENS, CAM
    PINEDO, HM
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (09) : 983 - 986
  • [5] Browder T, 2000, CANCER RES, V60, P1878
  • [6] Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain
    Broxterman, HJ
    Schuurhuis, GJ
    Lankelma, J
    Oberink, JW
    Eekman, CA
    Claessen, AME
    Hoekman, K
    Poot, M
    Pinedo, HM
    [J]. BRITISH JOURNAL OF CANCER, 1997, 76 (08) : 1029 - 1034
  • [7] Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells
    Broxterman, HJ
    Hoekman, K
    [J]. DRUG RESISTANCE UPDATES, 1999, 2 (03) : 139 - 141
  • [8] Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
    Curnis, F
    Sacchi, A
    Borgna, L
    Magni, F
    Gasparri, A
    Corti, A
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (11) : 1185 - 1190
  • [9] Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel:: Selective activation by the tumor-associated protease plasmin
    de Groot, FMH
    van Berkom, LWA
    Scheeren, HW
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) : 3093 - 3102
  • [10] Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin
    de Groot, FMH
    de Bart, ACW
    Verheijen, JH
    Scheeren, HW
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) : 5277 - 5283